Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Recursion Pharmaceuticals ( (RXRX) ).
On June 18, 2025, Recursion Pharmaceuticals held its annual meeting of stockholders where key proposals were voted on. Stockholders elected three Class I directors to serve until 2028, approved the executive compensation plan, and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025. These decisions are expected to influence the company’s governance and financial oversight in the coming years.
The most recent analyst rating on (RXRX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Recursion Pharmaceuticals stock, see the RXRX Stock Forecast page.
Spark’s Take on RXRX Stock
According to Spark, TipRanks’ AI Analyst, RXRX is a Neutral.
Recursion Pharmaceuticals shows promise with strong revenue growth and strategic partnerships, but faces significant challenges with profitability and operational efficiency. Technical indicators suggest potential downward momentum, and the negative P/E ratio highlights valuation concerns. Despite these challenges, recent corporate actions and a strategic focus on high-potential projects provide a cautiously optimistic outlook.
To see Spark’s full report on RXRX stock, click here.
More about Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on leveraging advanced computational techniques to accelerate drug discovery and development.
Average Trading Volume: 23,346,625
Technical Sentiment Signal: Sell
Current Market Cap: $2.03B
Find detailed analytics on RXRX stock on TipRanks’ Stock Analysis page.